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ABSTRACT: Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated.
Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this
neglected disease. The benzoxaborole chemotype has previously delivered clinical candidates for the treatment of other parasitic
diseases. Here, we describe the development and optimization of this series, leading to the identification of compounds with potent
in vitro and in vivo antileishmanial activity. The lead compound (DNDI-6148) combines impressive in vivo efficacy (>98% reduction
in parasite burden) with pharmaceutical properties suitable for onward development and an acceptable safety profile. Detailed mode
of action studies confirm that DNDI-6148 acts principally through the inhibition of Leishmania cleavage and polyadenylation
specificity factor (CPSF3) endonuclease. As a result of these studies and its promising profile, DNDI-6148 has been declared a
preclinical candidate for the treatment of VL.
■ INTRODUCTION
Visceral leishmaniasis (VL) is a poverty-linked disease,1 and
occurs primarily in poor populations across Asia, East Africa,
and South America.2 Current estimates suggest 50 000−90 000
new cases of VL occur each year.3 VL is caused by infection
with the protozoan parasites Leishmania donovani and
Leishmania infantum, with transmission mediated by the bite
of the female phlebotomine sand fly. Once the human host is
infected, parasites survive and multiply within macrophages,
leading to symptoms including prolonged fever, enlarged
spleen and liver, substantial weight loss, and progressive
anemia.4 If left untreated, the vast majority of clinically
symptomatic VL patients die within months.
The current standard treatment for patients with VL in East
Africa is sodium stibogluconate (SSG) combined with
paromomycin (PM).4 In South-East Asia, the standard
treatment is liposomal amphotericin B (LAB), with paromo-
mycin and miltefosine as a second-line treatment option.5
While these combination approaches are more effective than
SSG monotherapy, the mainstay of VL treatment for many
years, they still have significant limitations such as cost, route
of administration (all given via the parenteral route apart from
the oral drug miltefosine), and toxicity. Consequently, there is
an ongoing need for effective new treatments that are easy to
administer via oral dosing, are effective against VL in different
regions of the world, have an improved safety profile, and are
affordable for the patients who require them. Research and
development for the treatment of VL has evolved rapidly in
recent years, with 5 drug candidates from 4 different classes
now in phase-1 clinical studies (Table 1).6
Here, we outline the optimization of a benzoxaborole series
toward a possible new therapy for VL. The benzoxaborole class
of compounds has already successfully delivered a clinical
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candidate (acoziborole, AN5568, 1, Figure 1) for the treatment
of stage 1 and stage 2 human African trypanosomiasis (HAT,
African sleeping sickness).11 Stimulated by the success of the
acoziborole program, modifications to the benzoxaborole
template were undertaken to identify novel compounds that
may have utility for the treatment of VL, leading to the
discovery of a preclinical candidate 23 (DNDI-6148). This
compound combines good in vitro potency against both L.
infantum and L. donovani alongside very high levels of in vivo
efficacy (>98% reduction in parasite burden) in hamster
models of infection. In addition, DNDI-6148 possesses
excellent pharmacokinetics and is predicted to have acceptable
human pharmacokinetics and an efficacious dose consistent
with the requirements of the published target candidate (TCP)
and target product (TPP) profiles for VL published by DNDi.
Clinical trials with DNDI-6148 are now underway.11
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of benzoxaborole target com-
pounds 3−31 consisted of amide bond formation between the
key intermediate 2 and an appropriately functionalized acid
(Scheme 1) using one of three coupling methods, whose
choice was driven by substrate compatibility: Method A
(HOBt/EDCI coupling), Method B (HATU coupling), and
Method C (acid chloride formation using SOCl2 followed by
coupling with intermediate 2). The synthesis of the carboxylic
acid intermediates R2CO2H is described in detail in the
Supplementary Information. Example 12 was synthesized using
Method A. Examples 4, 6−11, 13−15, 17−18, 20−21, 23−27,
and 29−30 were synthesized using Method B, while examples
5, 16, 19, 22, 28, and 31 were synthesized using Method C.
Preclinical candidate compound 23 was synthesized using a
4-step synthesis (Scheme 2).
Formation of the fused tetrazole 23-2 was achieved by the
reaction of 2-bromopyridine with sodium azide. Cyclo-addition
of 23-2 with ethyl 3-oxobutanoate gave the N1-substituted
triazole 23-3, which was hydrolyzed to the corresponding acid
23-4. Coupling benzoxaborole scaffold 2 using Method B gave
the final compound 23 in high overall yield.
Compound 1 was potent in in vitro assays against
Trypanosoma brucei, the etiological agent of HAT (EC50
value of 795 nM),12 but demonstrated only weak activity in
intramacrophage assays with both L. infantum and L. donovani
(Table 2). It should be noted that L. infantum-derived
infections can be refractory to some current drug therapies.
Thus, new compounds in development are screened against
both L. infantum and L. donovani at an early stage to ensure
efficacy. However, the close analogue 3 (SCYX-6759), lacking
the gem-dimethyl substitution on the benzoxaborole ring, was
considerably more potent in these assays.13
Previous studies demonstrated that compound 3 has low
clearance in multiple animal models and is efficacious in a
murine model of HAT.13 Consequently, compound 3 was
progressed to an L. infantum hamster model of VL infection
(Table 3).14 Compound 3 was highly efficacious at QD doses
of 50 and 100 mg/kg, virtually clearing all parasites from the
liver and spleen. However, reductions in parasite burden in the
bone marrow were more modest and thus failed to meet the
DNDi target candidate profile (TCP) of >95% reduction in
parasite burden. Therefore, additional benzoxaboroles were
synthesized to identify compounds that were highly efficacious
in all tissues across a broad dose range.
The simplified benzoxaborole ring system, with the gem-
dimethyl substitution on the benzoxaborole ring removed, was
retained in subsequent analogues and the amide substituent
became the focus for development. Replacing the lipophilic
aryl substituent with a more polar heteroaryl group was
investigated in detail to reduce the lipophilicity to values more
associated with orally bioavailable drugs.15 Consistent with this
design strategy, a range of substituted pyrazoles was
synthesized (Table 4). Excellent levels of in vitro potency
were achieved with compounds 4−6, which contain a
trifluoromethyl R1 substituent and a fluorinated N-alkyl R2
Table 1. Current Portfolio of VL Drug Candidates in Clinical Developmenta
compound ID compound class mechanism of action and/or molecular target organization
DNDI-61486 benzoxaborole CPSF3 DNDi/Pfizer
DNDI-06906 nitroimidazole bioactivation by NTR27 DNDi/TB Alliance
GSK3186899/DDD8536516,7 pyrazolopyrimidine CRK12 (cyclin-dependent kinase)8 GSK/DDU
GSK3494245/DDD13051436,8 imidazopyridine proteasome inhibitor9 GSK/DDU
LXE4089 triazolopyrimidine proteasome inhibitor10 Novartis
aDDU: Drug Discovery Unit, University of Dundee and GSK: GlaxoSmithKline.
Figure 1. Structures of acoziborole (1), early hit 3, and preclinical candidate DNDI-6148 (23).
Scheme 1. General Synthesis of Amides 4−31a
aReagents and conditions: Method A: HOBt, EDCI, N,N-diisopropy-
lethylamine (DIPEA), CH2Cl2, rt, 2 h, 66%; Method B: HATU,
DIPEA, N,N-dimethylformamide (DMF), rt, 16 h, 8−77%; and
Method C: (i) SOCl2, 50 °C, 4 h, (ii) DIPEA, tetrahydrofuran
(THF), rt, 16 h, 4−68%.
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substituent. Importantly, compounds 4−6 showed no evidence
of cytotoxicity (CC50 > 38 μM) in the counter-screen with
PMM. These analogues also had excellent in vitro metabolic
stability in HLM, but compounds 4 and 6 had poor stability in
hamster liver microsomes (HamLM), which precluded their
evaluation in the in vivo hamster model of VL. Compound 5
combined sufficient in vitro potency, selectivity index (SI), and
stability in both HLM and HamLM to be considered for
further progression. Compound 7 (R1 = Me) was slightly less
potent than its CF3 analogue 6, and this same trend was also
observed for the N-cyclobutyl examples 8 and 9 as well as for
the 2-pyridyl examples 11 and 12. However, the CF3-
substituted analogues 6, 9, and 12 were all more cytotoxic in
PMM than their CH3-substituted counterparts 7, 8, and 11.
Tetrahydropyranyl-substituted analogue 10 combined many of
the necessary properties, but HamLM stability was insufficient
to deliver enough in vivo exposure for efficacy studies.
Typically, a HamLM clearance of <100 μL/min/mg is required
to observe meaningful exposure in vivo. Further lipophilic aryl
R2 substituents such as 4-Cl-phenyl 13 and 2-MeO-phenyl 14
had potent in vitro L. infantum activity but were cytotoxic in
PMM and/or MRC5 cells. The pyrazole 15 exhibited a
significant drop in potency compared to its isomeric analogue
6, whereas the pyridyl-substituted compound 16 was slightly
more potent than its isomer 11. Further substituted pyridine
examples 17 and 18 were also potent and demonstrated good
SI. In addition, compounds 16−18 were stable in both HLM
and HamLM. Additional pyrazole isomers 19−21 all failed to
combine sufficient in vitro potency and weak cytotoxicity with
good metabolic stability.
Of the compounds made up to this point, 2-pyridyl-
substituted analogue 16 was one of the most interesting as it
combined good in vitro potency, low lipophilicity, promising
SI, and was stable in both HLM and HamLM. For the next set
of compounds, the 2-pyridyl substituent was retained and
further changes to the 5-membered heterocycle were
investigated (Table 5). Triazole 22, where R1 = H, showed
an encouraging improvement in both in vitro potency and
HamLM stability over pyrazole 16. The Me-substituted
example 23 had an even better profile with high levels of L.
infantum potency, no sign of cytotoxicity in PMM and MRC5,
and very high levels of metabolic stability in HLM and
HamLM. Further 1,2,3-triazoles demonstrated that the 2-
pyridyl substituent was important; for example, the phenyl
example 24 and 3-pyridyl example 27 had significantly weaker
in vitro potency. Substitution on the 2-pyridyl group could be
tolerated, with the 6-OMe analogue 25 showing an improved
potency profile but at the expense of metabolic stability. The 6-
Me compound 26 lost some potency and was therefore not
progressed to metabolic stability assessment. Furan example 28
was very potent, and although it did exhibit some cytotoxicity
in both PMM and MRC5, the high level of potency meant that
28 still retained a high SI. Despite being more lipophilic,
metabolic stability was retained in both HLM and HamLM
and, therefore, 28 was considered for further progression. The
isomeric furan 29 had slightly reduced potency and SI
compared to 28, and the thiophene 30 was highly cytotoxic
in MRC5 cells. The more polar oxadiazole 31 delivered a good
overall profile and was also considered for further progression.
Scheme 2. Synthesis of Compound 23a
aReagents and conditions: (i) NaN3, CuI, NaOAc, DMEDA, EtOH, H2O, 1 h, reflux, 94%; (ii) ethyl 3-oxobutanoate, NaOEt, EtOH, 48 h, reflux;
(iii) NaOH, H2O, EtOH, 20 h, 45 °C, 48% for (ii) and (iii); and (iv) 2, HATU, DIPEA, DMF, room temperature (RT), 3 h, 74%. Note, the
material subsequently used in the mode of action studies was prepared from commercially available 23-2 via a modification of this route (see
Scheme 5).
Table 2. Collated EC50 Values for Compounds 1, 3 and the








1 59 >64 >64
3 1.2 2.7 >64
23 1.4 1.8 >64
miltefosine 10 10 33
aGeometric mean value of at least three independent assays. PMM:
primary mouse macrophages.
Table 3. In Vivo Efficacy of Compound 3 in an L. infantum
Hamster Model of VL, after QD Dosing for 5 Daysa
reduction in parasite burden, %
dose (mg/kg) liver spleen bone marrow
25 87.8 81.8 81.6
50 97.4 95.0 91.2
100 98.6 96.0 88.3
an = 6 animals per group, results were expressed as a percentage
reduction in amastigote burden compared to vehicle-treated, infected
control animals.
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The most promising compounds from this SAR inves-
tigation, namely 5, 16, 23, 28, and 31, were also assessed for
their in vitro macrophage potency using intracellular L.
donovani (Table 6). Pleasingly, four of these compounds
retained excellent levels of L. donovani potency; however, the
oxadiazole 31 was about 5-fold weaker against L. donovani
compared with its L. infantum potency.
Compounds 5, 16, 23, 28, and 31 were also progressed to
hamster oral pharmacokinetic (PK) studies and an L. infantum
model of VL in hamsters (Table 7). Triazole 23 exhibited
noticeably higher exposure after a single oral dose of 50 mg/kg
Table 4. Antileishmanial Activity of Pyrazoles 4−21
MRC5a HLM HamLM
compound R1 R2 intramacrophage L. infantum EC50 (μM)
a PMMa CC50 (μM) CC50 (μM) SI
b Clint (μL/min/mg)
3 2.7 >64 >64 >24 0.8 n.d.
4 CF3 CF3 2.1 >64 >64 >31 <11.9 1,035
5 CF3 CH2CF3 1.6 50 >64 >40 <11.9 41
6 CF3 (CH2)2CF3 1.3 38 49 38 <11.9 114
7 CH3 (CH2)2CF3 5.7 >64 >64 >11 n.d. n.d.
8 CH3 c-butyl 16 >64 >64 >4 <11.9 57
9 CF3 c-butyl 0.59 32 26 53 <11.9 337
10 CF3 4-THP 3.0 >64 >64 >21 <11.9 109
11 CH3 2-pyridyl 5.7 >64 >64 >11 <11.9 n.d.
12 CF3 2-pyridyl 0.64 2.0 1.1 1.6 n.d. n.d.
13 CF3 4-Cl-phenyl 1.3 8.0 2.6 2 n.d. n.d.
14 CH3 2-MeO-phenyl 2.2 >64 15.7 7.3 n.d. n.d.
15 CH3 (CH2)2CF3 14 >64 >64 >5 <11.9 48
16 CH3 2-pyridyl 3.1 59 61 15 <11.9 57
17 CH3 2-pyridyl-6-OMe 1.4 >64 40 31 <11.9 40
18 CH3 2-pyridyl-6-Me 1.6 >64 41 25 <11.9 44
19 H 2-pyridyl 0.5 32 4.0 8 <11.9 253
20 CH3 2-pyridyl 34 >64 >64 >2 18 121
21 CH3 2-pyridyl 1.8 >64 54 31 14 106
miltefosine 10 33 >64 >6.2 n.d. n.d.
aGeometric mean value of at least two independent tests. bSelectivity index representing the ratio of CC50/EC50; data are presented as the
geometric mean value of ratios calculated using separate data from at least two independent tests. n.d., not determined.
Table 5. Antileishmanial Activity of Compounds 22−31
MRC5a HLM HamLM
compound R1 R2 intramacrophage L. infantum amastigote EC50 (μM)




22 H 2-pyridyl 1.7 >64 44.8 30 <11.9 18
23 CH3 2-pyridyl 1.8 >64 >64 >39 <11.9 <11.9
24 CH3 phenyl 37 >64 >64 >1.7 <11.9 n.d.
25 CH3 2-pyridyl-6-OMe 0.8 32 >64 >80 23 40
26 CH3 2-pyridyl-6-Me 6.4 >64 >64 >10 n.d. n.d.
27 CH3 3-pyridyl 38 >64 >64 >1.8 n.d. n.d.
28 CH3 2-pyridyl 0.5 49 18 37 <11.9 40
29 CH3 2-pyridyl 1.7 29 45 18 <11.9 82
30 CH3 2-pyridyl 0.6 32 2.3 4 <11.9 88
31 2-pyridyl 2.0 >64 >64 >32 19 12
aGeometric mean value of at least two independent tests. bSelectivity index representing the ratio of CC50/EC50; data are presented as the
geometric mean value of ratios calculated using separate data from at least two independent tests. n.d., not determined.
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compared with the other lead compounds, which is consistent
with its higher in vitro stability in HamLM and indicated that in
vitro metabolic clearance may be predictive of in vivo clearance
for this set of compounds.
All five compounds demonstrated excellent efficacy, with
parasitemia significantly reduced in all organs after a dose of 50
mg/kg BID for 5 days. Triazole 23 and furan 28 also
maintained excellent efficacy at a lower dosing of 25 mg/kg
BID, consistent with the combination of good potency and
high exposure observed for 23 and the very high potency of 28.
Extending the duration of treatment from 5 to 10 days for
compound 23 led to almost complete eradication of parasites
in the liver, spleen, and bone marrow. In contrast, the efficacy
profile of compound 28 was not improved by extending the
dosing period.
Compounds 23 and 28 were then studied in an L. donovani
hamster model (Table 8). Triazole 23 exhibited high levels of
efficacy in the liver and spleen when dosed orally at 50 mg/kg
BID for 5 days, although the reduction in parasite load in bone
marrow was lower than the target of 95%. However, by
extending the dosing period to 10 days, very high efficacy
across all three tissues was achieved at a dose of 25 mg/kg
BID. In addition, furan 28 achieved excellent efficacy in all
tissues at both 25 mg/kg BID and 50 mg/kg BID for 5 days.
These important data demonstrated that for both L. infantum
and L. donovani, potent in vitro and in vivo activity could be
achieved.
Compounds 23 and 28 were also assessed in mouse models
of L. donovani and L. infantum; data confirmed that the high
levels of efficacy observed in the chronic hamster model of
infection was also achieved in the acute mouse model (Table
9).
Based on their in vitro potency, metabolic stability, and in
vivo pharmacokinetic and efficacy profiles, compounds 23 and
28 were investigated in more detail to determine if either could
be progressed to further preclinical development. Encouraged
Table 6. Antileishmanial Activity of Selected Compounds against L. donovani
MRC5a
compound intramacrophage L. infantum EC50 (μM)
a intramacrophage L. donovani EC50 (μM)
a PMMa CC50 (μM) CC50 (μM) SI
b
5 1.6 1.0 53.8 >64 >64
16 3.1 1.2 >64 61.1 52
23 1.8 1.4 >64 >64 >46
28 0.5 0.4 54 18 45
31 2.0 9.4 >64 >64 >7
aGeometric mean value of at least two independent tests. bSelectivity index representing the ratio of CC50/EC50; data are presented as the
geometric mean value of ratios calculated using separate data from at least two independent tests.
Table 7. Oral Exposure and In Vivo Efficacy of Selected Compounds in an L. infantum Hamster Model of VL Following BID
Dosing for 5 and 10 Daysa
reduction in parasite burden, %
liver spleen bone marrow
compound dose (mg/kg), BID 5 days 10 days 5 days 10 days 5 days 10 days AUC0−24 after single p.o. dose of 50 mg/kg (h.ng/mL)
5 25 89.7 n.d. 90.0 n.d. 77.0 n.d. 21 000
50 99.7 n.d. 99.2 n.d. 98.0 n.d.
16 25 87.8 n.d. 87.7 n.d. 72.2 n.d. 7900*
50 99.6 n.d. 98.5 n.d. 95.1 n.d.
23 25 98.3 100 98.2 99.9 93.6 99.4 120 000
50 99.8 n.d. 99.9 n.d. 99.0 n.d.
28 25 98.9 99.4 97.8 96.9 95.7 84 21 000
50 99.9 n.d. 99.9 n.d. 99.1 n.d.
31 25 67.3 n.d. 69.0 n.d. 55.0 n.d. 21 000
50 99.4 n.d. 99.4 n.d. 99.7 n.d.
an = 6 animals per group, the results are expressed as a percentage reduction in amastigote burden compared to vehicle-treated, infected control
animals, *Study run using a single 25 mg/kg p.o. dose.
Table 8. In Vivo Efficacy of Selected Compounds in an L. donovani Hamster Model of VL Following BID Dosing for 5 and 10
Daysa
reduction in parasite burden, %
liver spleen bone marrow
compound dose (mg/kg), BID 5 days 10 days 5 days 10 days 5 days 10 days
23 25 n.d. 99.9 n.d. 99.8 n.d. 99.6
50 99.3 n.d. 98.6 n.d. 83.4 n.d.
28 25 95.9 n.d. 95.9 n.d. 94.5 n.d.
50 99.9 n.d. 100 n.d. 100 n.d.
an = 6 animals per group, results were expressed as a percentage reduction in amastigote burden compared to vehicle-treated, infected control
animals, n.d., not determined.
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by the outstanding in vivo efficacy of compound 28, a 14-day
exploratory toxicology study was conducted in male and female
Sprague-Dawley rats. Unfortunately, compound 28 caused
significant multiorgan toxicity following daily dosing of 25 mg/
kg and the NOAEL (No Observed Adverse Effect Level) was
not determined (<12.5 mg/kg). Consequently, further
development of compound 28 was halted.
One potential concern associated with compound 28 was
the presence of the furan, a functional group that can undergo
oxidative metabolism to reactive metabolites.16 Thus, 23 and
28 were investigated to determine potential routes of
metabolism and to understand if protein−ligand adducts
were formed when the compounds were incubated in
microsomes in the presence of glutathione. Metabolite
identification studies with compound 28 showed evidence of
ring-opening of the furan to an enone M-12 metabolite in all
species tested (rat, mouse, dog, human, hamster). This
metabolite has the potential to undergo conjugation to form
protein−ligand adducts (Scheme 3).
In contrast, incubation of triazole 23 with microsomes
indicated very limited metabolism, with only small amounts of
mono-oxidation and hydrolysis/oxidative deboronation ob-
served in dog and human microsomes, respectively (Scheme
4). No metabolism was detected in rat microsomes, and no
evidence of reactive metabolite formation was found in any
species.
In addition to the safety signals raised by a moderate in vitro
activity against the MRC5 cell line (Table 5) and the lack of
efficacy improvement when treatment duration was extended
in the hamster model (Table 7), these in vitro metabolic
studies clearly identified a potential weakness with furan 28
that may contribute to the observed in vivo toxicity. Therefore,
23 was prioritized for further evaluation. CYP inhibition was
weak (IC50 > 50 μM vs CYP1A2, 2C9, 2C19, 3A4, 2D6),
hERG selectivity was high (hERG inhibition < 20% at 30 μM),
and no activity > 50% was observed when 23 was tested in a
panel of 88 targets (Cerep panel, Figure S13) at a
concentration of 10 μM. Plasma-protein binding was moderate
and consistent across species (dog 87%, human 92%, mouse
93%, rat 92%, hamster 88%). Thermodynamic solubility in
physiologically relevant media was low to moderate (Fasted
State Simulated Intestinal Fluid, FaSSIF solubility = 5.4 μg/
mL, Fed State Simulated Intestinal Fluid, FeSSIF solubility =
6.3 μg/mL), and membrane permeability was good with no
evidence of P-gp-mediated efflux (MCDK efflux ratio of 0.7,
Table S3). Microsome and hepatocyte stability was excellent
across all species (Table 10), although hepatocyte stability was
slightly worse in dogs compared with rats, monkeys, and
humans. Compound 23 was also negative when tested in an
Ames assay (TA98 and TA100 bacterial strains) with and
without metabolic activation over a dose range from 1.5 to
1000 μg/well, suggesting no clastogenicity. To complete the
early safety profile of compound 23, a 14-day exploratory
toxicology study was conducted in male and female Sprague-
Dawley rats where the no adverse effect limit was set at 50 mg/
kg/day.
In vivo pharmacokinetics after i.v. and p.o. dosing was
determined in rats and dogs (Table 11 and Figure S12).
Clearance in rats was low (4.5 mL/min/kg) with compara-
tively higher clearance in dogs (13.7 mL/min/kg), in line with
the higher turnover in dog hepatocytes compared with rat
hepatocytes. Oral bioavailability in rats was very high,
indicating complete oral absorption. Bioavailability was
somewhat lower in dogs and not fully understood at this
point, but still acceptable for future progression of the
compound. Allometric scaling from available rat and dog PK
data suggests that compound 23 will have low clearance (Cl =
1−4 mL/min/kg) and moderate−high bioavailability (40−
90%) in humans. BID dosing in humans at 3−20 mg/kg is
predicted to achieve the efficacious exposure observed in the L.
infantum and L. donovani hamster and mouse models of VL.
Mode of Action Studies (MoA). MoA studies as an
integrated part of a drug discovery program can provide vital
information that can be used to combat the high failure rates
associated with the development of phenotypically active
compounds. The association of active compounds with defined
molecular targets during the development process can be
extremely powerful. Understanding compound MoA can allow
toxic liabilities associated with the target to be directly
assessed, prevent enrichment of drug candidates against the
same molecular target, and halt the development of inhibitors
with an unattractive or invalidated target. Furthermore, this
knowledge can inform future drug combination strategies.
Our previous studies with acoziborole (AN5568, 1), in
clinical development for HAT, revealed that this promising
benzoxaborole specifically targets the Cleavage and Poly-
adenylation Specificity Factor 3 (CPSF3) in T. brucei.17−19
Additional compounds from within this series were also shown
to target CPSF3, including 3.13,19 CPSF3 is an endonuclease
that forms part of the CPSF complex, involved in the control of
polyadenylation and trans-splicing of pre-mRNA. Indeed,
CPSF3 orthologues have also been identified as the molecular
targets of benzoxaboroles active against Plasmodium falcipa-
rum,20 Toxoplasma gondii,21 and Cryptosporidium spp.21 With
this in mind, we hypothesized that DNDI-6148 (23) might
Table 9. In Vivo Efficacy of Selected Compounds in L.
donovani and L. infantum Mouse Models of VL Following
BID Dosing for 5 Days
reduction in liver parasite burden
following 5 days of p.o. dosing
BIDa, %
compound dose (mg/kg), BID L. infantum L. donovani
23 25 96.1 97.1
50 98.6 99.7
28 25 n.d. 97.5
50 n.d. 99.5
an = 5 animals per group, the results were expressed as a percentage
reduction in parasite burden compared to vehicle-treated, infected
control animals, n.d., not determined.
Scheme 3. Metabolic Fate of Compound 28 in the Presence of Microsomes from Multiple Species
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also target this important endonuclease in L. donovani. To test
this hypothesis, we first assessed the potency of DNDI-6148
(23) against T. brucei bearing a mutation in the active site of
CPSF3 (Asn232His), previously demonstrated to confer
resistance to acoziborole (1).19 Bloodstream trypanosomes
bearing this specific mutation were 1.8-fold less sensitive to
DNDI-6148 (23) compared to wild-type parasites (Figure
2A). Similarly, trypanosomes overexpressing the wild-type
version of CPSF3 were 2.9-fold less sensitive to DNDI-6148
(23) (Figure 2B). Collectively, these data suggest that, like
acoziborole (1), this benzoxaborole specifically targets CPSF3
in T. brucei.
To determine if these boron-containing compounds
specifically target CPSF3 in L. donovani, transgenic promasti-
gotes were generated overexpressing either CPSF3WT or
CPSF3 bearing an Asn219His mutation, equivalent to the
Asn232His mutation in the T. brucei enzyme. Elevated levels of
the wild-type and mutated CPSF3 in these cell lines were
confirmed by label-free quantification (Figure S2). Over-
expression of CPSF3WT in L. donovani promastigotes did not
substantively affect susceptibility to either acoziborole (1)
(Figure 2C) or DNDI-6148 (23) (Figure 2D). However,
promastigotes overexpressing the mutated version of this
enzyme were significantly less sensitive to both compounds,
demonstrating a 5-fold and 3.6-fold reduction in susceptibility
to acoziborole (1) and DNDI-6148 (23), respectively (Figure
2C,D). The shift in potency observed with parasites over-
expressing mutated CPSF3 was found to be specific for
benzoxaboroles. Compound 3 elicited a similar shift in
potency, while the established N-myristoyltransferase inhibitor
DDD10009722 did not (Figure S3). The fact that this single
Asn219His mutation in the active site of CPSF3 has a marked
effect on the potencies of both acoziborole (1) and DNDI-
6148 (23) provides strong evidence that this endonuclease is
the molecular target of this preclinical candidate.
Precision Base Editing of LdCPSF3. We next utilized
precision base editing with Cas9 to further probe the
interactions between DNDI-6148 (23) and L. donovani
CPSF3. In the first instance, a template encoding a specific
Asn219His mutation was provided to repair a Cas9-induced
lesion within CPSF3. Transfected parasites were then selected
with DNDI-6148 (23) (6 μM). The resulting DNDI-6148-
resistant population was subcloned, genomic DNA was
harvested, and the CPSF3 was sequenced to ensure that the
desired edit had been successfully introduced. In all cases,
these parasites maintained the Asn219His encoded by the repair
template and were consistently 3-fold less sensitive to DNDI-
6148 (23) than wild-type (Table S2). As in our previous
studies with T. brucei CPSF3, attempts to edit Asn219 to Tyr to
mimic the human CPSF3 enzyme at this position were not
tolerated by L. donovani. However, using a degenerate repair
template, parasites were recovered, maintaining Asn219His and
also Glu229Val homozygous mutations. These doubly mutated
parasites were >5-fold less sensitive to DNDI-6148 (23)
(Table S2). Collectively, these data provide compelling
evidence that DNDI-6148 specifically targets the endonuclease
CPSF3 in L. donovani. These data are also consistent with a
recently published study reporting CPSF3 as amongst the top
“hits” following the selection of the Cos-Seq genome-wide
overexpression library with DNDI-6148.23
Molecular Modeling. A homology model of the L.
donovani CPSF3 was generated using the crystallographic
structure of the Thermus thermophilus TTHA0252 homologue
as a template (PDB code 3IEMFigure 3). The Leishmania
enzyme shares 30% sequence identity with this bacterial
homologue. The proposed binding mode for DNDI-6148 (23)
in the model is consistent with the binding of the
benzoxaborole acoziborole to the catalytic site of CPSF3
located at the interface of the metallo-β-lactamase and β-CASP
domains in T. brucei CPSF3.19 The site comprises two zinc
atoms coordinated by a network of conserved histidine and
aspartic acid residues. Interaction with a zinc-activated water
molecule leads to the formation of a negatively charged
tetrahedral boronate species that coordinates the zinc atoms
(Figure S4), mimicking the transition state of the phosphate of
the RNA substrate. The amide in position 6 of the
benzoxaborole moiety directs the pyridyl-triazole moiety of
Scheme 4. Metabolic Fate of Compound 23 in the Presence of Microsomes
Table 10. In Vitro Metabolic Stability Across Species for
Compound 23
species mouse rat dog human
microsome Clint (μL/min/mg protein) <11.9 <11.9 5.8 <11.9
hepatocyte Clint (μL/min/million cells) n.d. 0.7 2.4 0.5
Table 11. In Vivo Pharmacokinetics of 23 in Rat and Dog
species rata dogb
route of administration i.v. p.o. i.v. p.o.
clearance (mL/min/kg) 4.5 13.7
Vd (L/kg) 0.6 1.3
T1/2 (h) 2.8 1.5
F (%) 94 39
an = 3 male SD rats, 2 mg/kg i.v., 10 mg/kg p.o. bn = 2 male Beagle
dogs, 1 mg/kg i.v., 5 mg/kg p.o.
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DNDI-6148 (23) toward the area occupied by the terminal
uracil base of the RNA substrate and establishes a π-stacking
interaction with Tyr370 (Figure 3A). Additionally, the amide
NH forms a hydrogen bond with the hydroxyl group in the
Thr218 side-chain. There seems to be no direct interaction
between DNDI-6148 (23) and the Asn219 residue, where
mutation to His is associated with resistance (Figure 3B).
However, we propose that mutation to a bulkier His residue in
this position has a negative impact on DNDI-6148 (23)
binding due to steric clashes with the methyl pyridyl-triazole
moiety of the compound (Figure 3C). This likely prompts the
ligand to adopt a different binding mode where a hydrogen
bond with Thr218 is lost, the hydrophobic methyl is directed
toward the solvent, and the overall ligand conformation is
strained. Undoubtedly, there is a high degree of similarity
surrounding the proposed binding site of DNDI-6148 in the
parasite enzyme and the human homologue, with 21 identical
residues out of the 26 within 5 Å from the bound ligand,19
However, Asn219 in the parasite enzyme is replaced by a
tyrosine residue in the human homologue. This bulkier
tyrosine residue is likely to cause severe steric hindrance that
prevents DNDI-6148 from binding to the human and is
entirely consistent with the favorable selective toxicity profile
of this compound.
The second mutation (Glu229Val) is at the beginning of helix
7 in the β-CASP domain of CPSF3. Helix 7 is some way from
the catalytic site but is connected to the loop that contains
Thr218, Asn219, and Ile221, defining the pocket that recognizes
the pyridine ring of DNDI-6148 (23). In our models, a
mutation from Glu229 to Val would result in a structural
rearrangement of the loop, changing the morphology of the
binding site and ultimately impacting the ligand recognition
event.
■ CONCLUSIONS
We have optimized a series of benzoxaboroles and identified a
range of compounds with very potent in vitro antileishmanial
activity against L. infantum and L. donovani, starting from
benzamide-substituted compound 3. Variation of the amide
substituent was explored extensively, and a range of
heterocyclic amide groups was found to deliver potent in
vitro activity combined with good metabolic stability. Several
compounds were assessed in the L. infantum hamster model of
VL, with compound 23 standing out by exhibiting very high
levels of efficacy in all organs at doses of 25 mg/kg BID for 5
or 10 days. Additional in vivo studies in the L. donovani
hamster model also indicated high levels of efficacy,
demonstrating that 23 was equally efficacious against both
Leishmania species responsible for causing VL. Efficacy of 23
was also confirmed in L. donovani and L. infantum BALB/c
mouse models. Further study of compound 23 indicated that it
had excellent pharmacokinetics, a good in vitro safety profile,
and met all of the criteria in the DNDi TCP for VL.
Comprehensive MoA studies confirm that DNDI-6148 (23)
targets the endonuclease CPSF3, a previously unexploited drug
target in Leishmania spp. Consequently, 23 (DNDI-6148) was
Figure 2. Potency of DNDI-6148 (23) against wild-type and transgenic T. brucei and L. donovani. (A) EC50 values for DNDI-6148 (23) were
determined for wild-type T. brucei trypanosomes (closed circles) and T. brucei trypanosomes maintaining a mutated version of CPSF3 (Asn232His)
(open circles). EC50 values of 47 ± 0.9 and 90 ± 3.4 nM were determined for wild-type and transgenic trypanosomes, respectively. (B) EC50 values
of 67 ± 1 and 172 ± 3 nM were determined for DNDI-6148-treated wild-type trypanosomes (closed circles) and trypanosomes overexpressing the
wild-type version of CPSF3, respectively. (C) EC50 values of 2.5 ± 0.1, 2.8 ± 0.1, and 11.7 ± 0.4 μM were determined for acoziborole-treated wild-
type (open circles), CPSF3-overexpressing (blue circles), and CPSF3 (Asn219His)-overexpressing (red circles) L. donovani promastigotes,
respectively. (D) EC50 values of 411 ± 12, 508 ± 13, and 1674 ± 51 nM were determined for DNDI-6148-treated wild-type (open circles), CPSF3-
overexpressing (blue circles), and CPSF3 (Asn219His)-overexpressing (red circles) L. donovani promastigotes, respectively. All curves are the
nonlinear fits of data using a two-parameter EC50 equation provided by GraFit. EC50 values are the weighted mean ± standard deviation of at three
biological replicates (n = 3), with each biological replicate comprised of three technical replicates.
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nominated as a preclinical candidate and further development
toward clinical studies is ongoing. Furthermore, compound 23
demonstrates similar levels of in vitro and in vivo activity
against species of Leishmania responsible for causing cutaneous
leishmaniasis (CL), supporting the development of this
candidate for multiple forms of leishmaniasis.24 It should be
noted that we have also generated data that supports the
development of DNDI-6148 for Chagas’ disease. This
information will be disclosed in due course. In conclusion,
the data package for DNDI-6148 (23) provides every reason to
believe that this benzoxaborole can become a much-needed
safe oral treatment for patients suffering from this devastating
neglected tropical disease.
■ EXPERIMENTAL SECTION
Chemistry. Purity. All compounds reported in this study are >95%
pure as determined by high-performance liquid chromatography
(HPLC) analysis. HPLC chromatograms of a representative
compound (3) and all analogues used in in vivo experiments (5, 16,
23, 28, 31) are shown in the Supplementary Information (Figures
S6−S11).
General. Unless otherwise indicated, all reactions were magneti-
cally stirred under an inert atmosphere. All reagents, including
solvents, were used as received. Anhydrous solvents were dried in-
house by passing through activated alumina. Thin-layer chromatog-
raphy was performed on glass-backed precoated silica gel 60 plates,
and compounds were visualized using UV light or iodine. Silica gel
column chromatography was performed using 200−300-mesh silica
gel. Preparative HPLC was performed using Gilson-281 liquid
handlers equipped with one of four columns, chosen from (1)
Phenomenex Synergi C18 150 mm × 30 mm, 4 μm, (2) YMC-pack
ODS-AQ 150 mm × 30 mm, 5 μm, (3) Agela Venusil ASB C18 150
mm × 21.2 mm, 5 μm, or (4) Boston Symmetrix C18 ODS-R 150
mm × 30 mm, 5 μm; elution was performed with 0.225% (by
volume) of formic acid in water (solvent A) and acetonitrile (solvent
B); fractions containing products were lyophilized. NMR spectra were
recorded on a Bruker AVANCE 400 MHz spectrometer in the
solvents specified. Liquid chromatography−mass spectrometry (LC-
MS) spectra were recorded on an Agilent 1200 or Shimadzu 2020
spectrometer equipped with electrospray ionization, quadrupole MS
detector, and Chromolith Flash RP-18e 25 mm × 2.0 mm column,
eluting with 0.0375% (by volume) of trifluoroacetic acid (TFA) in
water (solvent A) and 0.01875% (by volume) of TFA in acetonitrile
(solvent B). Analytical HPLC was performed using a Shimadzu
LC20AB machine and one of two columns, chosen from (1) Xtimate
C18 2.1 mm × 30 mm, 3 μm or (2) CHROM-MATRIX Innovation
C18 2.1 mm × 30 mm, 2.6 μm; elution was performed with 0.0375%
(by volume) of TFA in water (solvent A) and 0.01875% (by volume)
of TFA in acetonitrile (solvent B). The purity of final compounds was
≥96%, as determined by HPLC. Unless otherwise stated, final
compounds were isolated as amorphous solids without collection of
melting point data.
General Procedures for the Preparation of Amides. General
Procedure A. To a solution of the corresponding acid (14.4 mmol, 1.0
equiv), HOBt (17.3 mmol, 1.2 equiv), EDCI (17.3 mmol, 1.2 equiv),
and DIPEA (36.1, 2.5 equiv) in dichloromethane (DCM) (30 mL)
was added 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol (14.4 mmol, 1.0
equiv). The reaction mixture was stirred at room temperature for 2 h.
Water (100 mL) was added, and the reaction mixture was extracted
with DCM (100 mL × 3). The combined organic extracts were
washed with brine (100 mL × 2), dried with anhydrous Na2SO4,
filtered, and concentrated in a vacuum to give the crude product,
which was purified by silica gel chromatography or preparative HPLC.
General Procedure B. To a solution of the corresponding acid (1.5
mmol, 1.0 equiv), HATU (1.9 mmol, 1.3 equiv), and DIPEA (2.8
mmol, 1.8 equiv) in DMF (3 mL) was added 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol (1.5 mmol, 1.0 equiv). The mixture was stirred at
room temperature overnight. The mixture was purified by preparative
HPLC.
Figure 3. Molecular docking of DNDI-6148 into a model of the L. donovani CPSF3 active site. (A) Docking model for DNDI-6148 (23) (yellow
structure) bound to L. donovani CPSF3. Gray spheres represent zinc atoms, blue dotted lines indicate a π stacking interaction, and the purple
dotted line indicates a hydrogen bond interaction. (B) Close-up of key interactions involved in DNDI-6148 (23) (yellow structure) binding in the
active site of CPSF3. (C) Modified docking model illustrating a steric clash between DNDI-6148 (23) (red patch) and the His residue (yellow) in
Asn219His substituted CPSF3. The wild-type CPSF3 structure is shown in green.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c01437
J. Med. Chem. 2021, 64, 16159−16176
16167
General Procedure C. A solution of the corresponding acid (10.5
mmol) in SOCl2 (40 mL) was stirred at 50 °C for 4 h. The mixture
was concentrated in a vacuum to give acyl chloride, which was used
directly in the next step. To a solution of 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol (1.2 g, 8.1 mmol) and DIPEA (2.9 mL, 16.7
mmol) in THF (30 mL) was added the acid chloride (8.1 mmol).
The mixture was stirred at room temperature for 16 h. Water (100
mL) was added, and the reaction mixture was extracted with EtOAc
(100 mL × 3). The combined organic extracts were washed with
brine (100 mL × 2), dried with anhydrous Na2SO4, filtered, and
concentrated in a vacuum to give the crude product, which was
purified by silica gel chromatography or preparative HPLC.
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1,3-bis-
(trifluoromethyl)-1H-pyrazole-4-carboxamide (4). The title com-
pound was synthesized according to method B using a mixture of 1,3-
bis(trifluoromethyl)-1H-pyrazole-4-carboxylic acid and 1,5-bis-
(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (4 g, 16 mmol),
HATU (7.3 g, 19.2 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol
2 (2.9 g, 19.2 mmol), DIPEA (4.1 g, 32 mmol), and DMF (30 mL) to
yield 6.5 g of crude product as a yellow solid. 2 g of the crude product
was purified by prep-HPLC to yield 4 as a white solid (200 mg).
HPLC: 100% pure. MS (ESI) m/z = 380.1 [M + 1]+. 1H NMR (400
MHz, DMSO-d6) δ = 10.54 (s, 1H), 9.44 (s, 1H), 9.32 (brs, 1H),
8.18 (s, 1H), 7.65 (d, J = 7.2 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 4.98
(s, 2H). HRMS (ES+): calcd for C13H9B1F6N3O3 [M+H]
+ 380.0641,
found 380.0644 (0.75 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-(2,2,2-
trifluoroethyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (5).
To a cold solution of 6-amino-3,3-dimethylbenzo[c][1,2]oxaborol-
1(3H)-ol 2 (22.7 g, 152.3 mmol) and DIPEA (39.3 g, 305.2 mmol) in
THF (500 mL) was added a solution of 1-(2,2,2-trifluoroethyl)-3-
(trifluoromethyl)-1H-pyrazole-4-carbonyl chloride (42.7 g, 152.5
mmol) in THF (150 mL) dropwise. The mixture was stirred at
room temperature for 4 h and concentrated in a vacuum to a residue
that was recrystallized from MeCN and water to yield 5 as a gray solid
(41.1 g, 68%). HPLC: 98% pure. MS (ESI) m/z = 394.2 [M+H]+. 1H
NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.27 (s, 1H), 8.72 (s,
1H), 8.16 (s, 1H), 7.66 (dd, J = 2.0, 8.0 Hz, 1H), 7.39 (d, J = 8.4 Hz,
1H), 5.48 (q, J = 9.2 Hz, 2H), 4.97 (s, 2H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(trifluor-
omethyl)-1-(3,3,3-trifluoropropyl)-1H-pyrazole-4-carboxamide (6).
The title compound was synthesized according to method B using 3-
(trifluoromethyl)-1-(3,3,3-trifluoropropyl)pyrazole-4-carboxylic acid
6 (18.0 g, 65.2 mmol), HATU (34.7 g, 91.3 mmol), 1-hydroxy-3H-
2,1-benzoxaborol-6-amine 2 (10.7 g, 71.8 mmol), DIPEA (16.9 g,
131.0 mmol), and DMF (150 mL) to give a residue. The residue was
purified by silica gel chromatography (elution with ethyl acetate/
petroleum ether/AcOH = 1: 3: 0.1) to give the crude product, which
was recrystallized from MeOH to yield 6 as a white solid (9.60 g,
36.2%). HPLC: 99% pure. MS (ESI) m/z = 408.1 [M + 1]+. 1H NMR
(400 MHz, DMSO-d6): δ 10.22 (s, 1H), 9.25 (s, 1H), 8.66 (s, 1H),
8.17 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 4.96
(s, 2H), 4.56 (t, J = 6.8 Hz, 2H), 3.02 (m, 2H). HRMS (ES+): calcd
for C15H13B1F6N3O3 [M+H]
+ 408.0954, found 408.0957 (0.70 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-methyl-
1-(3,3,3-trifluoropropyl)-1H-pyrazole-4-carboxamide (7) and N-(1-
Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-1-(3,3,3-
trifluoropropyl)-1H-pyrazole-4-carboxamide (15). The title com-
pounds were synthesized according to method B using a mixture of 3-
methyl-1-(3,3,3-trifluoropropyl)-1H-pyrazole-4-carboxylic acid and 5-
methyl-1-(3,3,3-trifluoropropyl)-1H-pyrazole-4-carboxylic acid (469
mg, 2.1 mmol), HATU (890 mg, 2.3 mmol), 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol 2 (300 mg, 2.0 mmol), HATU (890 mg, 2.3
mmol), DIPEA (520 mg, 4.0 mmol), and DMF (5 mL) to yield the
crude product, which was purified by preparative HPLC to give 7
(207 mg, 29%) as a white solid and 15 (205 mg, 29%) as a white
solid.
7: HPLC: 99% pure. MS (ESI) m/z = 354[M+H]+. 1H NMR (400
MHz, DMSO-d6): δ = 9.77 (s, 1H), 9.21 (s, 1H), 8.42 (s, 1H), 8.14
(s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.97 (s,
2H), 4.38 (t, J = 6.8 Hz, 2H), 2.90 (m, 2H), 2.40 (s, 3H). HRMS (ES
+): calcd for C15H16B1F3N3O3 [M+H]
+ 354.1237, found 354.1240
(0.90 ppm).
15: HPLC: 99% pure. MS (ESI) m/z = 354[M+H]+. 1H NMR
(400 MHz, DMSO-d6): δ = 9.79 (s, 1H), 9.22 (s, 1H), 8.16 (s, 1H),
8.12 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 4.96
(s, 2H), 4.35 (t, J = 6.8 Hz, 2H), 2.87 (m, 2H), 2.57 (s, 3H).
HRMS (ES+): calcd for C15H16B1F3N3O3 [M+H]
+ 354.1237,
found 354.1240 (0.90 ppm).
Cyclobutyl-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-
yl)-3-methyl-1H-pyrazole-4-carboxamide (8). The title compound
was synthesized according to method B using cyclobutyl-3-methyl-
1H-pyrazole-4-carboxylic acid (201.0 mg, 1.1 mmol), 6-aminobenzo-
[c][1,2]oxaborol-1(3H)-ol 2 (167.0 mg, 1.1 mmol), HATU (543.0
mg, 1.4 mmol), DIPEA (180.0 mg, 1.4 mmol), and DMF (8 mL) to
yield the crude product, which was purified by preparative HPLC to
yield 8 as a white solid (96.6 mg, 28%). HPLC: 99% pure. MS (ESI)
m/z = 312.1 [M +H]+. 1H NMR (400 MHz, DMSO-d6): δ 9.71 (s,
1H), 9.21 (s, 1H), 8.43 (s, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.67 (dd, J =
8.4, 2.0 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 4.96 (s, 2H), 4.80 (m, 1H),
2.40 (m, 7H), 1.82 (m, 2H). HRMS (ES+): calcd for
C16H19B1N3O3 [M+H]
+ 312.1519, found 312.1523 (1.13 ppm).
1-Cyclobutyl-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-
yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide (9). The title
compound was synthesized according to method B using 1-
cyclobutyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (565
mg, 2.4 mmol), HATU (1.2 g, 3.2 mmol), 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol 2 (430.0 mg, 2.9 mmol), DIPEA (805.0 mg, 6.2
mmol), and DMF (4 mL) to yield the crude product, which was
purified by preparative HPLC to yield 9 as a white solid (278.0 mg,
32%). HPLC: 100% pure. MS (ESI) m/z = 366.0 [M + 1]+. 1H NMR
(400 MHz, DMSO-d6) δ = 10.16 (s, 1H), 9.25 (s, 1H), 8.68 (s, 1H),
8.16 (s, 1H), 7.63 (dd, J = 1.6, 8.0 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H),
4.99 (m, 1H), 4.96 (s, 2H), 2.47 (m, 4H), 1.86 (m, 2H). HRMS (ES
+): calcd for C16H16B1F3N3O3 [M+H]




mide (10). The title compound was synthesized according to method
B using 1-(tetrahydro-2H-pyran-4-yl)-3-(trifluoromethyl)-1H-pyra-
zole-4-carboxylic acid (900 mg, 3.4 mmol), HATU (1.9 g, 5.1
mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (507 mg, 3.4
mmol), and DIPEA (880 mg, 6.8 mmol) to yield the crude product,
which was purified by preparative HPLC to yield 10 as a pink solid
(358.6 mg, 26.7%). HPLC: 100% pure. MS (ESI) m/z = 396.0 [M +
1]+. 1H NMR (400 MHz, DMSO-d6) δ = 10.16 (s, 1H), 9.26 (s, 1H),
8.68 (s, 1H), 8.16 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0
Hz, 1H), 4.96 (s, 2H), 4.58 (m, 1H), 4.00 (m, 2H), 3.50 (t, J = 11.0
Hz, 2H), 2.07 (m, 2H), 1.96 (m, 2H). HRMS (ES+): calcd for C 17
H18 B1Fe 3N>3 O4 [M+H]
+ 396.1342, found 396.1346 (0.89 ppm).
N-(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)-3-methyl-1-
(pyridine-2-yl)-1H-pyrazole-4-carboxamide (11). The title com-
pound was synthesized according to method B using 3-methyl-1-
(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (211 mg, 1.04 mmol),
HATU (400 mg, 1.05 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-
ol 2 (155 mg, 1.04 mmol), and DIPEA (0.27 mL, 1.56 mmol) to yield
the crude product, which was triturated with DCM. The precipitated
product was collected by filtration to give 11 (198 mg 54%) as an off-
white solid. 1H NMR (DMSO-d6 with 0.05% v/v tetramethylsilane
(TMS), 400 MHz): δ 2.52 (s, 3H, CH3), 4.97 (s, 2H, CH2), 7.37 (d,
1H, Ar, J = 8.0 Hz), 7.42 (ddd, 1H, ArH, J = 7.6 Hz, J = 5.2 Hz, J =
1.2 Hz), 7.73 (dd, ArH, J = 8.4 Hz, J = 2.0 Hz), 7.94 (d, 1H, ArH, J =
8.0 Hz), 8.03 (dd, 1H, ArH, J = 8.0 Hz, J = 1.6 Hz), 8.21 (d, 1H, ArH,
J = 2.0 Hz), 8.54 (m, 1H, ArH), 9.47 (s, 1H, ArH), 9.70 (s, 1H, OH),
10.06 (s, 1H, NH).
6-(((1-(Pyridin-2-yl)-3-(trifluoromethyl)-1H-pyrazole-4-carbonyl)-
oxy)amino)benzo[c][1,2]oxaborol-1(3H)-ol (12). The title com-
pound was synthesized according to method A using 1-(pyridin-2-
yl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (200.0 mg, 0.78
mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (120.0 mg, 0.8
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mmol), HOBt (126.4 mg, 0.9 mmol), EDCI (172.8 mg, 0.9 mmol),
DIPEA (201.0 mg, 1.6 mmol), and DMF (5 mL) to yield the crude
product, which was purified by preparative HPLC to yield 12 as a
white solid (200.0 mg, 66%). HPLC: 99% pure. MS (ESI) m/z = 389
[M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 10.41 (s, 1H), 9.66 (s,
1H), 9.26 (s, 1H), 8.63 (m, 1H), 8.26 (d, J = 1.6 Hz, 1H), 8.15 (m,
1H), 8.04 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 8.0, 2.0 Hz, 1H), 7.58 (m,
1H), 7.40 (d, J = 8.4 Hz, 1H), 5.00 (s, 2H). HRMS (ES+): calcd for C
17H13 B1F3 N4O3 [M+H]
+ 389.1033, found 389.1036 (0.82 ppm).
6-(((1-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-4-
carbonyl)oxy)amino)benzo[c][1,2]oxaborol-1(3H)-ol (13). The title
compound was synthesized according to method B using 1-(4-
chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
(200 mg, 0.7 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2
(134 mg, 0.9 mmol), HATU (315.0 mg, 0.83 mmol), HATU
(315.0 mg, 0.83 mmol), TEA (0.2 mL, 1.4 mmol), and DMF (5 mL)
to yield the crude product, which was purified by preparative HPLC
to yield 13 as a white solid (180.0 mg, 62%). HPLC: 99% pure. MS
(ESI) m/z = 422.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ
10.32 (s, 1H), 9.32 (s, 1H), 9.26 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 8.8
Hz, 2H), 7.68 (m, 3H), 7.41 (d, J = 8.0 Hz, 1H), 4.98 (s, 2H).
N-(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)-1-(2-methoxy-
phenyl)-3-methyl-1H-pyrazole-4-carboxamide (14). The title com-
pound was synthesized according to method B using 1-(2-
methoxyphenyl)-3-methyl-1H-pyrazole-4-carboxylic acid (300 mg,
1.29 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (192 mg,
1.29 mmol), HATU (491 mg, 1.29 mmol), DIPEA (250 mg, 1.94
mmol), and DMF (3 mL) to yield the crude product, which was
triturated with DCM. The precipitated product was collected by
filtration and recrystallized from CHCl3 to give 14 (190 mg, 41%) as
an off-white solid. 1H NMR (CDCl3 with 0.05% v/v TMS, 400
MHz): δ 2.50 (s, 3H, CH3), 3.93 (s, 3H, CH3), 4.97 (s, 2H, CH2),
7.09−7.14 (m, 1H, ArH), 7.29−7.32 (m, 1H, ArH), 7.36−7.43 (m,
2H, ArH), 7.67−7.72 (m, 2H, ArH), 8.14 (d, 1H, ArH, J = 1.6 Hz),
8.88 (s, 1H, ArH), 9.23 (s, 1H, OH), 9.89 (s, 1H, NH).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-(pyridin-2-yl)-1H-pyrazole-4-carboxamide (16). A solution of 5-
methyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (15.0 g, 73.9
mmol) in SOCl2 (100 mL) was stirred at 50 °C for 4 h. The mixture
was concentrated in a vacuum to give acyl chloride, which was used
directly in the next step. To a solution of 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol 2 (11.0 g, 73.8 mmol) and DIPEA (15 mL) in
DCM (30 mL) was added a solution of acyl chloride in DCM (20
mL) dropwise at 0 °C. The mixture was stirred at room temperature
for 1 h. The precipitate was filtered and the cake was washed with
MTBE (100 mL) and water (50 mL), dried in a vacuum and
recrystallized from THF (50 mL) to yield 16 as a white solid (16.0 g,
65%). HPLC: 100% pure. MS (ESI) m/z = 335.2 [M+H]+. 1H NMR
(400 MHz, DMSO-d6) δ 9.99 (s, 1H), 9.24 (s, 1H), 8.57 (dd, J = 5.2,
1.2 Hz, 1H), 8.36 (s, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.07 (m, 1H),
7.84 (d, J = 8.0 Hz, 1H), 7.72 (m, 1H), 7.40 (m, 1H), 7.37 (d, J = 8.4
Hz, 1H), 4.98 (s, 2H), 2.85 (s, 3H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-(6-me-
thoxypyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxamide (17). The
title compound was synthesized according to method B using 1-(6-
methoxypyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (2.3 g,
10 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (1.50 g, 10
mmol), HATU (3.8 g, 10 mmol), DIPEA (3.9 g, 30 mmol), and DMF
(20 mL) to yield the crude product, which was purified by preparative
HPLC to yield 17 as a white solid (2.8 g, 77%). HPLC: 99% pure. MS
(ESI) m/z = 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.97
(s, 1H), 9.22 (s, 1H), 8.34 (s, 1H), 8.16 (d, J = 1.6 Hz, 1H), 7.94 (t, J
= 8.0 Hz, 1H), 7.73 (dd, J = 8.0, 2.0 Hz, 1H), 7.45 (d, J = 7.6 Hz,
1H), 7.39 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 4.98 (s, 2H),
3.93 (s, 3H), 2.94 (s, 3H). HRMS (ES+): calcd for C18H18B1
N4O4 [M+H]
+ 365.1421, found 365.1425 (1.07 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-(6-methylpyridin-2-yl)-1H-pyrazole-4-carboxamide (18). The title
compound was synthesized according to method B using 5-methyl-1-
(6-methylpyridin-2-yl)-1H-pyrazole-4-carboxylic acid (100.0 mg, 0.5
mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (82.0 mg, 0.5
mmol), HATU (210 mg, 0.6 mmol), DIPEA (89 mg, 0.7 mmol), and
DMF (3 mL) to yield the crude product, which was purified by
preparative HPLC to yield 18 as a white solid (34.8 mg, 22%).
HPLC: 96% pure. MS (ESI) m/z = 349.1 [M + 1]+. 1H NMR (400
MHz, DMSO-d6): δ 9.95 (s, 1H), 9.21 (s, 1H), 8.33 (s, 1H), 8.15 (s,
1H), 7.92 (t, J = 7.6 Hz, 1H) 7.72 (d, J = 10.0 Hz, 1H), 7.61 (d, J =
8.0 Hz, 1H), 7.35 (m, 2H), 4.97 (s, 2H), 2.84 (s, 3H), 2.54 (s, 3H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(pyridin-
2-yl)-1H-pyrazole-5-carboxamide (19). To a solution of 6-
aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (357.0 mg, 2.4 mmol) and
DIPEA (619.0 mg, 4.8 mmol) in MeCN (10 mL) was added a
solution of 3-(pyridin-2-yl)-1H-pyrazole-5-carbonyl chloride (500 mg,
2.4 mmol) in MeCN (10 mL) dropwise. The mixture was stirred at
60 °C for 20 h. The mixture was concentrated in a vacuum to give a
crude product, which was purified by preparative HPLC to yield 19 as
a white solid (28.4 mg, 3.7%). HPLC: 96% pure. MS (ESI) m/z =
321.1 [M + 1]+. 1H NMR (400 MHz, DMSO-d6) δ = 8.65 (d, J = 4.4
Hz, 1H), 8.21 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.90 (t, J = 7.8 Hz,
1H), 7.82 (dd, J = 2.0, 8.0 Hz, 1H), 7.51 (s, 1H), 7.38 (m, 2H), 4.98
(s, 2H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-methyl-
3-(pyridin-2-yl)-1H-pyrazole-5-carboxamide (20) and N-(1-Hy-
droxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-methyl-5-(pyridin-
2-yl)-1H-pyrazole-3-carboxamide (21). The title compounds were
synthesized according to method B using a mixture of 1-methyl-3-
(pyridin-2-yl)-1H-pyrazole-5-carboxylic acid and 1-methyl-5-(pyridin-
2-yl)-1H-pyrazole-3-carboxylic acid (300 mg, 1.5 mmol), HATU (722
mg, 1.9 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (222.0
mg, 1.5 mmol), DIPEA (361.0 mg, 2.8 mmol), and DMF (3 mL) to
yield the crude product, which was purified by preparative HPLC to
give 20 (123 mg, 25%) as a white solid and 21 (40.7 mg, 8%) as a
white solid.
20: HPLC: 99% pure. LC-MS (ESI) m/z = 335.1 [M + 1]+, t =
0.931 min. 1H NMR (400 MHz, DMSO-d6) δ = 10.42 (s, 1H), 9.29
(s, 1H), 8.63 (d, J = 4.4 Hz, 1H), 8.23 (s, 1H), 7.97 (d, J = 8.0 Hz,
1H), 7.87 (m, 1H), 7.78 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.37 (m,
1H), 4.98 (s, 2H), 4.20 (s, 3H). HRMS (ES+): calcd for C17H16B1
N4O3 [M+H]
+ 335.1315, found 335.1319 (1.06 ppm).
21: HPLC: 99% pure. LC-MS (ESI) m/z = 335.1 [M + 1]+, t =
1.026 min. 1H NMR (400 MHz, DMSO-d6) δ = 10.18 (s, 1H), 9.26
(s, 1H), 8.73 (d, J = 4.8 Hz, 1H), 8.23 (s, 1H), 7.95 (m, 2H), 7.80 (d,
J = 6.8 Hz, 1H), 7.45 (m, 1H), 7.36 (m, 2H), 4.97 (s, 2H), 4.28 (s,
3H). HRMS (ES+): calcd for C17H16B1N4O3 [M+H]
+ 335.1315,
found 335.1319 (1.06 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-(pyridin-
2-yl)-1H-1,2,3-triazole-4-carboxamide (22). To a solution of 6-
amino-3,3-dimethylbenzo[c][1,2]oxaborol-1(3H)-ol 2 (1.6 g, 10.5
mmol) and DIPEA (2.7 g, 21.0 mmol) in THF (20 mL) was added a
solution of 1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carbonyl chloride (2.2
g, 10.5 mmol) in THF (80 mL) at 0 °C. The mixture was stirred at
room temperature for 4 h. The solvent was removed in a vacuum and
the residue was recrystallized with MeCN and water to yield 22 as a
gray solid (1.7 g, 51%). HPLC: 100% pure. MS (ESI) m/z = 321.9
[M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 10.61 (s, 1H), 9.39 (s,
1H), 9.27 (s, 1H), 8.67 (d, J = 4.4 Hz, 1H), 8.20 (m, 3H), 7.82 (dd, J
= 8.8, 2.0 Hz, 1H), 7.63 (m, 1H), 7.41 (d, J = 8.4 Hz, 1H), 4.98 (s,
2H). HRMS (ES+): calcd for C15H12B1N5O3Na1 [M+Na]
+ 344.0931,
found 344.0934 (0.90 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxamide (23). The title
compound was synthesized according to method B using 5-methyl-
1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxylic acid (3.3 g, 16.2
mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (2.9 g, 19.4
mmol), HATU (8.0 g, 21.0 mmol), DIPEA (4.2 g, 32.3 mmol),
and DMF (30 mL) to yield the crude product, which was purified by
preparative HPLC to yield 23 as a yellow solid (4.0 g, 74.1%). HPLC:
100% pure. MS (ESI) m/z = 336.1[M + 1]+. 1H NMR (400 MHz,
DMSO-d6): δ 10.59 (s, 1H), 9.25 (s, 1H), 8.70 (dd, J = 4.8, 0.8 Hz,
1H), 8.28 (s, 1H), 8.19 (t, J = 8.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H),
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7.83 (dd, J = 8.0, 2.0 Hz, 1H), 7.67 (d, J = 5.2 Hz, 1H), 7.38 (d, J =
8.0 Hz, 1H), 4.97 (s, 2H), 2.81 (s, 3H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-phenyl-1H-1,2,3-triazole-4-carboxamide (24). The title com-
pound was synthesized according to method B using 5-methyl-1-
phenyl-1H-1,2,3-triazole-4-carboxylic acid (870.0 mg, 4.3 mmol), 6-
aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (870.0 mg, 5.8 mmol),
HATU (1.7 g, 4.5 mmol), DIPEA (1.7 g, 13.2 mmol), and DMF
(16 mL) to yield the crude product, which was purified by preparative
HPLC to yield 24 as a white solid (0.61 g, 43%). HPLC: 98% pure.
MS (ESI) m/z = 335 [M + 1]+. 1H NMR (400 MHz, DMSO-d6): δ
10.56 (s, 1H), 9.27 (s, 1H), 8.29 (s, 1H), 7.84 (dd, J = 8.0, 2.0 Hz,
1H), 7.69 (m, 5H), 7.40 (d, J = 8.4 Hz, 1H), 4.99 (s, 2H) 2.61 (s,
3H). HRMS (ES+): calcd for C17H16B1N4O3 [M+H]
+ 335.1315,
found 335.1319 (1.06 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-1-(6-me-
thoxypyridin-2-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide (25).
The title compound was synthesized according to method B using 1-
(6-methoxypyridin-2-yl)-5-methyl-1H-1,2,3-triazole-4-carboxylic acid
(150.0 mg, 0.6 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2
(114.0 mg, 0.77 mmol), HATU (365.0 mg, 1.0 mmol), DIPEA (165.0
mg, 1.3 mmol), and DMF (3 mL) to yield a crude product, which was
purified by preparative HPLC to yield 25 as a white solid (134.5 mg,
58%). HPLC: 99% pure. MS (ESI) m/z = 366.1 [M+H]+. 1H NMR
(400 MHz, DMSO-d6): δ 10.56 (s, 1H), 9.24 (s, 1H), 8.28 (m, 1H),
8.06 (t, J = 8.0 Hz, 1H), 7.83 (dd, J = 8.0, 2.0 Hz, 1H), 7.58 (d, J =
7.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 4.98
(s, 2H), 3.95 (s, 3H), 2.91 (s, 3H). HRMS (ES+): calcd for
C17H17B1N5O4 [M+H]
+ 366.1374, found 366.1377 (0.93 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-(6-methylpyridin-2-yl)-1H-1,2,3-triazole-4-carboxamide (26).
The title compound was synthesized according to method B using
5-methyl-1-(6-methylpyridin-2-yl)-1H-1,2,3-triazole-4-carboxylic acid
(80.0 mg, 0.4 mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2
(89.0 mg, 0.6 mmol), HATU (228.0 mg, 0.6 mmol), DIPEA (103.0
mg, 0.8 mmol), and DMF (3 mL) to yield the crude product, which
was purified by preparative HPLC to yield 26 as a yellow solid (45
mg, 35%). HPLC: 95% pure. MS (ESI) m/z = 350.2 [M+H]+. 1H
NMR (400 MHz, DMSO-d6): δ 10.56 (s, 1H), 9.24 (s, 1H), 8.28 (s,
1H), 8.07 (t, J = 8.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0
Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 4.98 (s,
2H), 2.82 (s, 3H), 2.59 (s, 3H). HRMS (ES+): calcd for
C17H17B1N5O3 [M+H]
+ 350.1424, found 350.1428 (1.01 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
1-(pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamide (27). The title
compound was synthesized according to method B using 5-methyl-
1-(pyridin-3-yl)-1H-1,2,3-triazole-4-carboxylic acid (150.0 mg, 0.7
mmol), 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (109.0 mg, 0.7
mmol), HATU (380 mg, 1.0 mmol), DIPEA (188.0 mg, 1.5 mmol),
and DMF (5 mL) to yield the crude product, which was purified by
preparative HPLC to yield 27 as a white solid (154.6 mg, 63%).
HPLC: 100% pure. MS (ESI) m/z = 336.2 [M+ 1]+. 1H NMR (400
MHz, DMSO-d6) δ 10.60 (s, 1H), 9.23 (s, 1H), 8.93 (d, J = 2.4 Hz,
1H), 8.85 (d, J = 4.8 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.20 (d, J =
7.6 Hz, 1H), 7.83 (d, J = 10.0 Hz, 1H), 7.74 (m, 1H), 7.39 (d, J = 8.0
Hz, 1H), 4.98 (s, 2H), 2.63 (s, 3H). HRMS (ES+): calcd for
C16H15B1N5O3 [M+H]
+ 336.1268, found 336.1271 (0.89 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-methyl-
4-(pyridin-2-yl)furan-2-carboxamide (28). To a solution of 3-
methyl-4-(pyridin-2-yl)furan-2-carboxylic acid (1.7 g, 8.3 mmol) in
DCM (20 mL) was added (COCl)2 (2.4 mL, 25.1 mmol) and DMF
(50 μL). The mixture was stirred at room temperature for 8 h. The
mixture was concentrated in a vacuum to give acyl chloride. To a
solution of 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (1.2 g, 8.1
mmol) and DIPEA (2.9 mL, 16.7 mmol) in THF (30 mL) was added
acyl chloride. The mixture was stirred at room temperature for 16 h.
Water (150 mL) was added and the mixture was extracted with
EtOAc (150 mL × 4). The combined organic extracts were washed
with brine (100 mL × 2), dried with anhydrous Na2SO4, filtered, and
concentrated in a vacuum to give a residue. The residue was purified
by silica gel chromatography (elution with DCM/EtOH = 50: 1) to
give a crude product, which was recrystallized from MeCN (100 mL)
to yield 28 as a white solid (1.6 g, 57%). HPLC: 98% pure. MS (ESI)
m/z = 335.0 [M + 1]+. 1H NMR (400 MHz, DMSO-d6) δ 10.20 (s,
1H), 9.24 (s, 1H), 8.65 (d, J = 4.0 Hz, 1H), 8.37 (s, 1H), 8.18 (s,
1H), 7.87 (m, 1H), 7.75 (m, 1H), 7.30 (m, 3H), 4.96 (s, 2H), 2.62 (s,
3H).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-
4-(pyridin-2-yl)furan-2-carboxamide (29). To a solution of 5-
methyl-4-(pyridin-2-yl)furan-2-carboxylic acid (5.7 g, 28.1 mmol),
DIPEA (7.5 g, 58.1 mmol), and HATU (16.0 g, 42.1 mmol) in DMF
(60 mL) was added 6-aminobenzo[c][1,2]oxaborol-1(3H)-ol 2 (4.2
g, 28.2 mmol). The mixture was stirred at room temperature
overnight. Water (200 mL) was added and a lot of solid formed. The
suspension was filtered and the cake was collected and purified by
preparative HPLC to yield 29 as a white solid (6.5 g, 65.6%). HPLC:
100% pure. MS (ESI) m/z = 334.9 [M + 1]+. 1H NMR (400 MHz,
DMSO-d6) δ 10.20 (s, 1H), 9.27 (s, 1H), 8.65 (d, J = 4.0 Hz, 1H),
8.17 (s, 1H), 7.88 (m, 2H), 7.75 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H),
7.30 (m, 1H), 4.98 (s, 2H), 2.76 (s, 3H). HRMS (ES+): calcd for
C18H16B1N2O4 [M+H]
+ 335.1203, found 335.1206 (0.86 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-methyl-
4-(pyridin-2-yl)thiophene-2-carboxamide (30). The title compound
was synthesized according to method B using 3-methyl-4-(pyridin-2-
yl)thiophene-2-carboxylic acid (100 mg, 0.46 mmol), 6-aminobenzo-
[c][1,2]oxaborol-1(3H)-ol 2 (80 mg, 0.54 mmol), HATU (200 mg,
0.53 mmol), DIPEA (300 mg, 2.33 mmol), and DMF (2 mL) to yield
the crude product, which was purified by preparative HPLC to yield
30 as a white solid (63.8 mg). HPLC: 99% pure. MS (ESI) m/z =
351.1 [M + 1]+. 1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H),
9.27 (s, 1H), 8.70 (d, J = 4.0 Hz, 1H), 8.11 (s, 1H), 8.03 (s, 1H), 7.74
(t, J = 2.0 Hz, 1H), 7.70 (m, 2H), 7.40 (m, 2H), 4.98 (s, 2H), 2.55 (s,
3H). HRMS (ES+): calcd for C18H16B1N2O3S1 [M+H]
+ 351.0975,
found 351.0978 (0.94 ppm).
N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-5-(pyridin-
2-yl)-1,3,4-oxadiazole-2-carboxamide (31). To a reaction mixture of
5-(pyridin-2-yl)-1,3,4-oxadiazole-2-carbonyl chloride were added
DIPEA (6.8 g, 52.7 mmol) and a solution of 1-hydroxy-3H-2,1-
benzoxaborol-6-amine 2 (2.5 g, 17 mmol) in MeCN (50 mL) at 0 °C.
The mixture was stirred at 0 °C for 1 h. The reaction mixture was
quenched by adding water (100 mL) at room temperature and
extracted with EtOAc (100 mL × 2). The combined organic extracts
were washed with brine (200 mL × 2), dried over Na2SO4, filtered,
and concentrated under reduced pressure to give a residue. The
residue was dispersed in DCM (20 mL), filtered, and the cake was
dried under reduced pressure to give a crude product, which was
purified by preparative HPLC to yield 31 as a white solid (1.9 g,
45%). HPLC: 99% pure. MS (ESI) m/z = 323.2 [M+H]+. 1H NMR
(400 MHz, DMSO-d6): δ 11.36 (s, 1H), 9.32 (s, 1H), 8.84 (d, J = 2.4
Hz, 1H), 8.32 (m, 1H), 8.25 (s, 1H), 8.12 (m, 1H), 7.85 (m, 1H),
7.72 (d, J = 3.6 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 5.00 (s, 2H).
Biology. Compounds and Reagents. For in vitro assays,
compound stock solutions were prepared in 100% dimethyl sulfoxide
(DMSO) at 20 mM. Compounds were serially prediluted (2-fold or
4-fold) in DMSO, followed by a further (intermediate) dilution in
demineralized water to assure a final in-test DMSO concentration of
<1%. For in vivo studies, compounds were formulated in 2% ethanol,
1 mol equiv NaOH, and dextrose (5% solution) when administrated
orally to mice, hamsters, and dogs or intravenously (pH adjusted to 7)
to rats and dogs. For oral administration in rats, 0.5% (w/v)
methylcellulose and 0.1% (w/v) sodium dodecyl sulfate in Milli-Q
water were used. Miltefosine was formulated in water at 20 mg/mL.
Cell Cultures. Primary peritoneal mouse macrophages (PMM)
were collected two days after peritoneal stimulation with a 2% potato
starch suspension. MRC5SV2 cells (diploid human embryonic lung
fibroblasts) were cultured in minimal essential medium (MEM)
containing Earle’s salts, supplemented with L-glutamine, NaHCO3,
and 5% inactivated fetal calf serum. All cultures and assays were
conducted at 37 °C under an atmosphere of 5% CO2.
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Parasites. L. infantum (MHOM/MA/67/ITMAP263) and L.
donovani (MHOM/ET/67/L82) were maintained in the golden
(Syrian) hamster (Mesocricetus auratus). Ex vivo amastigotes were
collected from the spleen of an infected donor hamster using two
centrifugation purification steps: 230g for 10 min, keeping the
supernatant layer, and 4100g for 30 min, keeping the pellet. The
spleen parasite burden was assessed using the Stauber technique.25
For in vitro assays, the inoculum was prepared in RPMI-1640
medium, supplemented with 200 mM L-glutamine, 16.5 mM
NaHCO3, and 5% inactivated fetal calf serum. For the in vivo
model, an infection inoculum containing 2 × 107 amastigotes/100 μL
was prepared in phosphate-buffered saline (PBS).
Animals. Female golden hamsters for the in vivo model of visceral
leishmaniasis were purchased from Janvier, France (body weight 80−
100 g). This study using laboratory rodents was carried out in strict
accordance with all mandatory guidelines (EU directives, including
the Revised Directive 2010/63/EU on the protection of Animals used
for Scientific Purposes that came into force on 01/01/2013, and the
declaration of Helsinki in its latest version) and was approved by the
ethical committee of the University of Antwerp, Belgium (UA-ECD
2011-74). Female golden hamsters for the pharmacokinetic study
were purchased from Vital River, Beijing, China. This study was
conducted following institutional review and in accordance with
institutional and national guidelines at WuXi AppTec (the Institu-
tional Animal Care and Use Committee (IACUC)). Balb/c mice for
the in vivo model of visceral leishmaniasis (LSHTM) were purchased
from Charles River, U.K., and related studies were conducted under
license PPL 70/8427 from the U.K. Home Office.
Intramacrophage L. infantum and L. donovani Assays. The
assay was performed in sterile 96-well microtiter plates, each well
containing 10 μL of the compound dilution and 190 μL of the PMM/
amastigote inoculum (3 × 104 cells/4.5 × 105 parasites per well).
Parasite multiplication was compared to untreated infected controls
(100% growth) and uninfected controls (0% growth). After five-day
incubation, total parasite burdens were microscopically assessed after
staining the cells with a 10% Giemsa solution. The results were
expressed as a percentage reduction in parasite burden compared to
untreated control wells. EC50 values were determined using an
extended dose range (2-fold compound dilutions, 8-point concen-
tration curve). Miltefosine was used as the reference drug.26 For
selected compounds, this assay format was also run using the L.
donovani inoculum.
In Vitro MRC5 and PMM Cytotoxicity Assays. Assays were
performed in sterile 96-well microtiter plates, each well containing 10
μL of the compound dilution and 190 μL of MRC5SV2 or PMM
inoculum (3 × 104 cells/mL). Cell growth was compared to untreated
controls (100% growth) and assay-media controls (0% growth). After
three-day incubation, cell viability was assessed fluorometrically by
adding resazurin (50 μL/well of a stock solution in phosphate buffer
(50 μg/mL)), incubating for 4 h and measuring fluorescence (λex 550
nm, λem 590 nm). The results were expressed as a percentage
reduction in cell growth compared to untreated control wells. EC50
values were determined using an extended dose range (2-fold
compound dilutions, 8-point concentration curve) to a highest
concentration of 64 μM. Tamoxifen was included as the reference
drug.
In Vivo Hamster Model of Visceral Leishmaniasis. Female golden
hamsters were randomly allocated to experimental groups of six
animals each, based on body weight. At the start of the experiment
(Day 0), each animal was infected with L. infantum or L. donovani
inoculum, delivered by intracardial injection. Six hamsters were
assigned to the vehicle-treated, infected control group. Six hamsters
were assigned per group (1 group/compound) for the evaluation of
compound and miltefosine. At Day 21 postinfection (21 dpi), all
animals in each group were dosed orally for five (or ten) consecutive
days (21−25 dpi): compound was dosed at 25−50 mg/kg b.i.d.;
miltefosine was dosed at 40 mg/kg q.d. At Day 35 (10 days after the
final oral dose), all animals were euthanized and autopsies were
conducted. The study evaluated the following parameters.
1. Adverse effects: all animals were observed daily for the
occurrence/presence of adverse effects.
2. Body weight: all animals were weighed twice per week to
monitor general health.
3. Parasite burden: amastigote burdens in each target organ
(liver, spleen, and bone marrow) were determined at Day 35.
The organs of individual animals were weighed (except for
bone marrow). Impression smears were stained with Giemsa
for microscopic examination of the total amastigote burden,
defined as the mean number of amastigotes per cell multiplied
by the number of cells counted (minimum 500 nuclei); the
results were expressed as a percentage reduction in amastigote
burden compared to vehicle-treated, infected control animals.
In Vivo Mouse Model of Visceral Leishmaniasis. Female BALB/c
mice were infected with 2 × 107 L. donovani amastigotes/0.2 mL i.v.
harvested from the spleen of an infected donor RAG1B6 mouse
(LSHTM). After 7 days, the mice were treated with miltefosine or
DNDI-6148 for 5 consecutive days. Five days after the final dose,
mice were humanely killed, liver and spleens were dissected and
weighed, and impression smears were made for the calculation of
parasite burden (Stauber equation).25
Liver Microsome Stability. Tests were performed by WuXi
AppTec, China. Test compounds (at 1 μM) or positive controls
(testosterone, propafenone, and diclofenac) were incubated at 37 °C
with liver microsomes from Balb/c mouse, golden (Syrian) hamster,
Sprague-Dawley rat, Beagle dog, or human in the presence of a
NADPH regenerating system and phosphate buffer (100 mM, pH
7.4) at 0.4 or 0.8 mg/mL microsomal protein. The samples were
removed at time intervals from 0 to 60, 90, or 120 min and
immediately mixed with cold methanol supplemented or not with acid
(3% formic acid) and centrifuged prior to analysis by LC-MS/MS
using tolbutamide or propranolol as internal standards.
Hepatocyte Stability. Tests were performed by WuXi AppTec,
China. Following a viability check of cryopreserved hepatocytes from
Sprague-Dawley rat, Beagle dog, or human, test compounds (at 1
μM) or positive controls 7-ethoxycoumarin and 7-hydroxycoumarin
(at 3 μM) were incubated at 37 °C, 5% CO2 with hepatocytes in
Williams’Medium E. Following incubation of 15, 30, 60, 90, 120, 180,
and 240 min, reactions were stopped by the addition of acetonitrile,
the samples were centrifuged, and LC-MS/MS analysis was
conducted using tolbutamide as an internal standard.
Metabolite ID Studies. Metabolite identification studies were
conducted at WuXi AppTec, China. DNDI-6148 was incubated at 10
μM in the presence of Beagle dog and Sprague-Dawley rat liver
microsomes (1 mg/mL) for 60 min. Following precipitation with a
solution of formic acid and acetonitrile, metabolites were identified by
LC-UV-MSn (n = 1−2).
CYP Inhibition Studies. The study was conducted by WuXi
AppTec, Co., China, using the time-dependent (TDI) method. For
detecting any IC50 shift, the test compound (at concentrations of
0.05−50 μM) was first preincubated for 30 min at 37 °C with pooled
human liver microsomes in the presence or not of NADPH. Following
incubation with substrates (phenacetin for 1A2, diclofenac for 2C9, S-
(+) mephenytoin for 2C19, dextromethorphan for 2D6, and
midazolam or testosterone for 3A4), reactions were stopped by
adding ice-cold acetonitrile, the samples were analyzed for the
formation of metabolites by LC-MS/MS, and the percentage of
inhibition was determined.
hERG Inhibition. An automated patch-clamp method (QPatch
HTX) was used by WuXi AppTec, China. Chinese hamster ovary cells
expressing hERG potassium channels were incubated at room
temperature with test compounds (0.12, 0.37, 1.11, 3.33, 10, and
30 μM, in triplicate) or amitriptyline as a positive control.
Plasma-Protein Binding. Tests were conducted by WuXi AppTec,
Co., China, using the equilibrium dialysis method and a 96-well plate
format. The test compound (at 2 μM, in triplicate) in solution in
plasma (Balb/c mouse, golden (Syrian) hamster, Sprague-Dawley rat,
Beagle dog or human) was dialyzed against 100 mM phosphate-
buffered saline (pH 7.4) on a rotating plate incubated for 6 h at 37
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°C. Following the precipitation of protein with acetonitrile or
acetonitrile/methanol containing both 1% phosphoric acid, the
amount of compound present in each compartment was quantified
by LC-MS/MS.
Thermodynamic Solubility. The thermodynamic solubility was
measured by WuXi AppTec, China. Aliquots of the compound
DMSO stock (10 mM) were transferred to fasted state simulated
intestinal fluid (FaSSIF) buffer (pH 6.5) or fed state simulated
intestinal fluid (FeSSIF) buffer (pH 5.0), and the mixtures were
shaken for 24 h at room temperature. Following sampling by a
Whatman filter device, the compound concentrations were
determined by UV spectroscopy.
Membrane Permeability. Bidirectional permeability tests with
MDCK-MDR1 cells were performed by WuXi AppTec, Co., China.
The test compound, at a concentration of 2 μM in 0.4% DMSO/
HBSS buffer with 10 mM HEPES pH 7.4, was applied to the apical or
basolateral side of the cell monolayer. Permeation of the compound
from A to B direction or B to A direction was determined in triplicate
over a 150 min incubation at 37 °C and 5% CO2 (95% humidity).
Test and reference compounds were quantified by LC-MS/MS
analysis based on the peak area ratio of analyte/internal standard.
Ames Assay. Mini-Ames reverse mutation screens were conducted
by WuXi AppTec, Co., China. Two Salmonella typhimurium strains
(TA98 and TA100) were employed, both in the presence and absence
of metabolic activation (induced rat liver S9). Test compounds were
assessed at doses of 1.5, 4, 10, 25, 64, 160, 400, and 1000 μg per well,
2-aminoanthracene, 2-nitrofluorene, and sodium azide were used as
positive controls, and the negative control was DMSO.
In Vivo Pharmacokinetic Studies. In vivo pharmacokinetic studies
were conducted at WuXi AppTec, Co., China.
Hamster. Compounds were formulated as a homogenous
suspension in 2% ethanol, 1 mol equiv NaOH, dextrose (5%
solution), and dosed twice p.o. on a single day (8 h apart, 25 or 50
mg/kg, BID) in female golden Syrian hamsters. The K2-EDTA
anticoagulant was added to blood samples collected from 0.25 to 36 h,
which were processed to plasma and stabilized with phosphoric acid
(1% final) before analysis by LC-MS/MS. PK parameters were
calculated using WinNonlin software (version 6.3).
Rat. DNDI-6148 was formulated in 2% ethanol, 1 mol equiv
NaOH, dextrose (5% solution), and administrated to male Sprague-
Dawley rats, either i.v. after filtration and pH adjustment (at 2 mg/
kg), or p.o. as a homogenous suspension (at 10 mg/kg). The K2-
EDTA anticoagulant was added to blood samples collected at
predose, 0.083 (i.v. only), 0.25, 0.5, 1, 2 (p.o. only), 4, 8, and 24 h,
and were processed to plasma and stabilized with phosphoric acid
(1% final) before analysis by LC-MS/MS. PK parameters were
calculated using WinNonlin software (version 6.21 and 6.3).
Dog. DNDI-6148 was administrated intravenously at 1 mg/kg and
orally at 5 mg/kg to male Beagle dogs. The formulation for the i.v. leg
was 2% ethanol, 1.0 mol equiv NaOH, dextrose (5% solution) filtered,
and adjusted to pH 7, and for the p.o. leg, the formulation was 2%
ethanol, 1.0 mol equiv NaOH, and dextrose (5% solution). The K2-
EDTA anticoagulant was added to blood samples collected at
predose, 0.033 (i.v. only), 0.083 (p.o. only), 0.25, 0.5, 1, 3, 6, 9, and
24 h, and were stabilized with phosphoric acid (1% final) before
analysis by LC-MS/MS. PK parameters were calculated using
WinNonlin software (version 6.3).
MoA Studies. Synthesis of DNDI-6148, N-(1-Hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)-5-methyl-1-(pyridin-2-yl)-1H-
1,2,3-triazole-4-carboxamide (23) Used in MoA studies. All NMR
spectra for the compounds and intermediates made in the course of
these studies are available upon request.
The samples of DNDI-6148 used in the MoA studies were
prepared using a three-step sequence (Scheme 5) modified from a
synthetic route previously reported by Jacobs and co-workers.27 In
brief, triazole 23-3 was prepared using an optimized flow chemistry
procedure to alleviate the potential risk of explosion when heating low
molecular weight organic azides. Note, tetrazole 23-2 is converted to
the azide reactant (IV) under the thermal reaction conditions.28
Treatment with LiOH hydrolyzed the ester function of 23-3 to give
lithium salt II, which was converted to DNDI-6148 (23) by reaction
with aniline 2, T3P, and base.
Ethyl 5-Methyl-1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxylate
(23-3). A solution of tetrazolo[1,5-a]pyridine (23-2) (144 mg, 1.2
mmol) and ethyl 3-oxobutanoate (I) (1.56 g, 5.99 mmol) in EtOH
(10 mL) and a solution of NaOEt (245 mg, 3.6 mmol) in EtOH (10
mL) were mixed in a 1:1 ratio and applied to the flow coil (Vapourtec
RS-400 flow chemistry system). The reaction mixture was then heated
at 150 °C with a residence time of 2 h. The crude product mixture
was collected into a vial and acidified to pH 5 by the addition of HCl
(2N aq.). The reaction mixture was then concentrated under reduced
pressure and directly purified by silica flash column chromatography
(10:90 → 50:50 EtOAc:heptane), affording ester 23-3 as a colorless
solid (110 mg, 38% yield). 1H NMR (500 MHz, CDCl3) δ 8.59 (1H,
d, J = 4.75 Hz), 8.00−7.93 (2H, m), 7.42 (1H, t, J = 6.03 Hz), 4.47
(2H, q, J = 7.12 Hz), 2.92 (3H, s), 1.45 (3H, t, J = 7.10 Hz). 13C
NMR (126 MHz, CDCl3) δ 161.7, 150.2, 148.5, 139.7, 139.1, 137.4,
124.1, 118.3, 61.0, 14.3, 11.0. HRMS (ES+): m/z [M+H]+ calcd for
C11H13N4O2, 233.1033; found, 233.1061.
Lithium 5-Methyl-1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxy-
late (II). A solution of LiOH (1 M, aq, 0.31 mL, 0.31 mmol) was
Scheme 5. Synthetic Route to DNDI-6148 (23) Employed for the Material Used in the MoA Studiesa
aReagents and conditions: (a) NaOEt, EtOH, 150 °C, 2 h (flow), 38%; (b) LiOH, THF/water, room temp., 16 h, 97%; and (c) 2, T3P, DIPEA,
DMF/EtOAc, RT, 16 h, 29%.
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added to a solution of ethyl 5-methyl-1-(pyridin-2-yl)-1H-1,2,3-
triazole-4-carboxylate (23-3) (72 mg, 0.31 mmol) in THF/water (4:1,
10 mL), and the resulting mixture was stirred at room temperature for
16 h. The reaction mixture was then concentrated under reduced
pressure, and the resultant aqueous residue was lyophilized to furnish
the title compound as a colorless solid (64 mg, 97%). 1H NMR (500
MHz, D2O) δ 8.74 (1H, d, J = 4.05 Hz), 8.28 (1H, t, J = 7.80 Hz),
7.84 (1H, d, J = 8.00 Hz), 7.79 (1H, dd, J = 7.15, 5.35 Hz), 2.67 (3H,
s). 13C NMR (126 MHz, D2O) δ 168.4, 149.0, 147.9, 141.9, 140.7,
137.6, 125.9, 120.6, 9.3. HRMS (ES+): m/z [M+H]+ calcd for
C9H9N4O2, 205.0720; found, 205.0686.
DNDI-6148, N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-
yl)-5-methyl-1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxamide (23).
Neat DIPEA (130 mg, 1.28 mmol) was added to a stirred suspension
of carboxylate II (45 mg, 0.214 mmol) and 6-aminobenzo[c][1,2]-
oxaborol-1(3H)-ol, hydrochloride (5) (59.6 mg, 0.321 mmol) in dry
DMF (3.0 mL) at room temperature. A solution of propylphosphonic
anhydride (50% w/v in EtOAc, 0.757 mL, 0.642 mmol) was then
added dropwise, and the resulting mixture was stirred for a further 16
h at room temperature. The reaction mixture was then concentrated
under reduced pressure and directly purified by silica flash column
chromatography (2:98 MeOH:CH2Cl2), affording the title compound
as a colorless solid (21.7 mg, 95% purity, 29% yield). The product was
further purified by reverse phase preparative HPLC (C18 silica, 5:95
→ 95:5 MeCN:water + 0.1% NH3) to give an assay/analytical sample
at >95% purity. 1H NMR (400 MHz, DMSO) δ 10.53 (1H, s), 9.20
(1H, s), 8.71 (1H, ddd, J = 4.86, 1.78, 0.72 Hz), 8.27 (1H, d, J = 1.76
Hz), 8.19 (1H, dt, J = 11.79, 1.87 Hz), 7.98 (1H, d, J = 8.08 Hz), 7.84
(1H, dd, J = 8.22, 2.02 Hz), 7.68 (1H, ddd, J = 7.51, 4.87, 0.95 Hz),
7.39 (1H, d, J = 8.32 Hz), 4.98 (2H, s), 2.82 (3H, s). 13C NMR (126
MHz, DMSO) δ 159.8, 149.8, 149.7, 149.5, 140.5, 139.4, 138.1,
137.7, 125.5, 124.3, 123.0, 121.9, 119.5, 70.2, 10.7 (note, the signal for
the benzene quaternary carbon atom directly linked to the boron
atom was not observed in the 13C NMR due to severe broadening
from scalar relaxation caused by the spin dynamics of the quadrupolar
11B nucleus). HRMS (ES+): m/z [M+H]+ calcd for C16H15BN5O3,
336.1262; found, 336.1271.
Cell Lines and Culture Conditions. The clonal L. donovani cell
line LdBOB (derived from MHOM/SD/62/1S-CL2D) was grown as
promastigotes at 28 °C, as described previously. Bloodstream form T.
brucei MiTat 1.2 clone 221a and its derived subline, 2T1, were
cultured at 37 °C in the presence of 5% CO2 in HMI9-T medium, as
described previously. T. brucei cell lines overexpressing CPSF3 and
overexpressing a mutated version of CPSF3 (Asn232His) were
generated as part of a previous study and cultured as described.19
Generation of L. donovani Transgenic Cell Lines. L. donovani
CPSF3 gene (LdBPK_343210.1) was custom synthesized by GeneArt
and ligated into the pIR1SAT vector via BglII restriction sites. Using
the Q5 mutagenesis kit (NEB) and the pIR1SAT-LdCPSF3WT
construct as a template, mutations encoding A655C and Asn219His
change to CPSF3WT were introduced. Mutations were introduced
using the specific primers 5′-GAGTACACGGCATCCGC-3′ and 5′-
TCCGCAATCAGGATGTCTGGT-3′ and as per manufacturers’
instructions. Wild-type and mutated pIR1SAT constructs were
digested with SwaI and transfected into L. donovani promastigotes,
as previously described. Resistant clones were selected with
nourseothricin (100 μg/mL), and two clones per transfection were
selected for further study.
CRISPR-Cas9 Generated Mutations in LdCPSF3. A cell line
constitutively expressing Cas9 and T7 RNA polymerase was
generated by transfecting 4 × 107 promastigotes with the pTB007
vector (10 μg), as previously described.29 Expression of Cas9 in
selected clones was confirmed by western blotting (Figure S1). In
addition, the CRISPR-Cas9 system in these parasites was confirmed
as functional following the successful tagging of the flagellar protein
PF16 with mNeonGreen, as previously described.29
To introduce specific mutations into CPSF3, 3 × 106 promastigotes
expressing Cas9 and T7 RNA were resuspended in a 110 μL of
Human T-Cell Nucleofector reagent and transfected with 18 μL of
sgRNA and 4 μg of template using the Amaxa Nucleofector
electroporator (program V-033). sgRNA was produced according to
the previously established protocol from the Gluenz lab,30 in which
the scaffold primer G00 and a gene-specific forward primer
(FwsgRNA) were used (Table S1). The sgRNA template and
templates introducing base edits are summarized in Table S1.
Twenty-four hours following transfection, DNDI-6148 was added to
cultures at 6 μM. Drug-selected populations were cloned by limiting
dilution, EC50s were determined, and genomic DNA was extracted.
The CPSF3 gene from CRISPR-edited parasites was amplified by
PCR, and the resulting products were sequenced.
In Vitro Drug Sensitivity Assays (MoA Studies). Drug
sensitivity assays with wild-type and transgenic T. brucei and L.
donovani cell lines were carried out as previously described.31,32
Confirmation of CPSF3 Overexpression Using MS. WT and
L. donovani promastigotes (3 × 108) overexpressing CPSF3 were
washed twice with PBS (1000 g, 4 °C, 5 min). The pellet was
resuspended in 1.5 mL of lysis buffer (50 mM potassium phosphate
buffer, pH 7.0, 1 mM EDTA, 1 mM DTT, and 1 × EDTA-free
complete protease inhibitors (Roche)). Parasites were biologically
inactivated by 3 × freeze/thaw cycles prior to lysis using a One-Shot
Cell Disruptor (Constant Systems) at 30 kpsi. Lysed cells were then
centrifuged (10 min, 4 °C, 15 000g), and the soluble material was
harvested. Soluble cell lysates (100 μg samples) were reduced by the
addition of tris(2-carboxyethyl)phosphine hydrochloride (TCEP, 25
mM final concentration) and incubated at 37 °C for 10 min. The
samples were then alkylated by the addition of iodoacetamide (25
mM final concentration) and incubated at RT for 1 h in the dark.
Alkylated samples were digested by the addition of 1:50
endoproteinase LysC (Wako, Japan) in 100 mM triethylammonium
bicarbonate (TEAB), followed by incubation at 37 °C for 6 h, then
the addition of 1:50 trypsin (1.50 dilution) and incubation at 37 °C
overnight. The resulting digested peptides were then vacuum-dried.
LC-MS/MS Analysis. Analysis of peptides was performed on a Q-
Exactive Plus mass spectrometer (Thermo Scientific) coupled with a
Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers used were
as follows: Buffer A (0.1% formic acid in Milli-Q water (v/v)) and
Buffer B (80% acetonitrile and 0.1% formic acid in Milli-Q water (v/
v)). Aliquots (15 μL per sample) were loaded at 10 μL/min onto a
PepMap nanoViper C18 column (100 μm × 2 cm, 5 μm, 100 Å,
Thermo Scientific) equilibrated with 98% Buffer A. The column was
washed for 5 min at the same flow rate and then was switched in line
with a Thermo Scientific, resolving PepMap RSLC C18 column (75
μm × 50 cm, 2 μm, 100 Å). Peptides were eluted at a constant flow
rate of 300 nL/min with a linear gradient of 2−35% Buffer B in 125
min, then to 98% in 127 min. The column was then washed with 98%
Buffer B for 20 min and re-equilibrated in 2% Buffer B for 17 min
prior to loading the next sample. The Q-Exactive Plus was used in the
data-dependent mode. The scan cycle comprised MS1 scan (m/z
range from 335−1600, with a maximum ion injection time of 20 ms, a
resolution of 70 000, and an automatic gain control (AGC) value of 1
× 106), followed by 15 sequential dependent MS2 scans (with an
isolation window set to 1.4 Da, resolution at 17 500, maximum ion
injection time at 100 ms, and AGC 2 × 105). The stepped collision
energy was set to 27 and fixed first mass to 100 m/z. Spectra were
acquired in a centroid mode and unassigned charge states. Charge
states above 6, as well as singly charged species, were rejected. To
ensure mass accuracy, the mass spectrometer was calibrated on day 1
of the analyses. LC-MS analysis was performed by the FingerPrints
Proteomics Facility (University of Dundee).
Data Analysis. MS data analysis was performed using MaxQuant
software (http://maxquant.org/, version 1.6.2.6a). Carbamidomethyl
(C), oxidation (M), acetyl (Protein N-term), deamidation (NQ), and
Gln -> pyro-Glu were set as variable modifications. Proteins were
identified by searching a protein sequence database containing T.
brucei brucei TREU927 annotated proteins (downloaded from
TriTrypDB 46, http://www.tritrypdb.org). LFQ and “match between
runs” features were enabled. Trypsin/P and LysC/P were selected as
the specific proteases with two potential missed cleavages. The FDR
threshold for peptides and proteins was 0.01. FTMS MS/MS mass
tolerance was set to 10 ppm, and ITMS MS/MS mass tolerance was
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0.6 Da. Protein abundance was obtained using LFQ intensity values.
LFQ intensities were calculated using at least 2 unique peptides. Data
was visualized using Perseus 1.6.2.1 (https://maxquant.org/perseus/
).
Homology Modeling and In Silico Docking Studies. To
identify suitable template structures for the generation of the L.
donovani CPSF3 homology model, the sequence UniProtKB
E9BRB9 was used to query the PDB using “BLAST” as implemented
in the NCBI blastp suite (https://blast.ncbi.nlm.nih.gov/). Endonu-
cleases from five different species, human CPSF73 (PDB code 2I7T
and 6M8Qsequence identity 54%), Saccharomyces cerevisiae CPSF
(PDB code 6I1Dsequence identity 47%), Pyrococcus horikoshii
CPSF3 (PDB code 3AF5sequence identity 29%), Cryptosporidium
hominis (PDB code 6Q55sequence identity 48%), and T.
thermophilus TTHA0252 (several structures available exemplified by
PDB code 3IEMsequence identity 30%), were identified as close
analogues that could be used as template structures. The T.
thermophilus structure is complexed with a stable RNA analogue
bound to the catalytic site located at the interface between the
metallo-β-lactamase and β-CASP domains, whereas one human, S.
cerevisiae and P. horikoshii structures are apo forms where the Zn2+-
containing binding site is inaccessible. The C. hominis structure is in
complex with a small boron-containing inhibitor (AN3661) and
where the binding site is still inaccessible to a larger ligand. One of the
human structures (6M8Q) is in complex with a small ligand that does
not interact with the two Zn2+ ions and adopts the binding mode that
causes structural rearrangements in loop regions adjacent to the
binding cavity. Thus, the T. thermophilus structure was selected as a
suitable template. The alignment between the amino acid sequence of
LdCPSF3 that of the T. thermophilus CPSF3 was manually curated
(Figure S5) and showed a sequence identity of 68% in the binding site
area. A homology model for LdCPSF3 was built using the knowledge-
based method in Prime in Schrödinger (Schrödinger Release 2019-3:
Schrödinger, LLC, New York, NY, 2020). Zinc atoms were modeled
into the structure but not the RNA substrate. Due to its empty p-
orbital, the boron atom in DNDI-6148 is a strong electrophile (Lewis
acid) that can react with solvent water molecules. The nucleophilic
attack of an activated water molecule on the trigonal boron atom leads
to the formation of a tetrahedral negatively charged boron species.
The three-dimensional structure of the hydroxylated form of DNDI-
6148 was built in Maestro, minimized with the OPLS3 force field, and
docked in the catalytic site of the LdCPSF3 model using GLIDE in
Schrödinger. Docking results were subjected to a restrained
minimization procedure with the OPLS3e force field, as implemented,
where each heavy atom was allowed to deviate by up to 0.5 Å from its
original position in the model.
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